Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Agios Pharmaceuticals Inc
AGIO | US
25.32
USD-0.42
-1.63%
AGIO | US
About Agios Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
25.32
Open
25.57
High
25.59
Low
24.92
Agios Pharmaceuticals Inc. a biopharmaceutical company engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat) an activator of wild-type and mutant pyruvate kinase (PK) enzymes for the treatment of hemolytic anemias; and AG-946 a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals Inc. was incorporated in 2007 and is headquartered in Cambridge Massachusetts.
View LessAGIO | US
Risk
99.6
Sharpe
-0.21
Luna's Score
49/100
Recommendation
Hold
Luna says (AGIO | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
114.7%1 month
99.6%3 months
62.3%6 months
95.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
2.47
Price to book
3.80
Debt to equity
0.10
Debt to assets
0.08
Ent. to EBITDA
-2.33
Ent. to rev.
64.08
PEG
-
Other Fundamentals
EBITDA
-399.10M
MarketCap
1.44B
MarketCap(USD)
1.44B
Div. yield
-
Op. margin
-1.23K
Erngs. growth
-
Rev. growth
28.40
Ret. on equity
-44.92
Short ratio
6.09
Short perc.
5.84
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
10.86
Range1M
11.43
Range3M
11.43
Volumes: Market Activity
Rel. volume
0.74
Price X volume
24.23M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.33 | - | Cheaper |
| Ent. to Revenue | 64.08 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.80 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 62.32 | - | Par |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 1.44B | - | Emerging |
